Improved Protease Partner Programs

        Pfizer

Catalyst signed a worldwide exclusive licensing agreement with Wyeth Pharmaceuticals, now a subsidiary of Pfizer, in June 2009.  Catalyst is responsible for discovery and research of novel FVIIa variants, including improved FVIIa proteases that may allow their use in a prophylactic setting for hemophilia patients and for the control of bleeding in normal patients in a surgical or trauma setting.  Pfizer is responsible for preclinical and clinical development, manufacturing and commercialization of resulting FVIIa products.